title: Sevelamer Hydrochloride for Tumor Lysis Syndrome-related Hyperphosphatemia.
abstract: BACKGROUND
  Tumour lysis syndrome is associated with high levels of uric acid, phosphate and potassium along with low levels of calcium and abnormal renal function. Sevelamer, an oral phosphate-binder is used in the treatment of hyperphosphatemia in children and adults on hemodialysis.
  
  
  METHODS
  Two children with T-cell acute lymphoblastic leukemia who presented with a high tumour load and developed tumour lysis syndrome.
  
  
  METHODS
  Both children received Rasburicase and Sevelamer hydrochloride. The serum phosphate reduced to normal levels within 24-48 hrs of initiation of sevelamer hydrochloride.
  
  
  CONCLUSIONS
  Sevelamer appears to be an effective treatment for hyperphosphatemia associated with tumour lysis syndrome.
authors.affiliation: Department of Pediatrics, Kasturba Medical College Hospital, Mangalore (Manipal University), Karnataka, India. Correspondence to: Dr Harsha Prasada L, Department of Pediatrics, Kasturba Medical College Hospital, Mangalore 575 001, Karnataka. Harsha.pl@manipal.edu.
authors.forename: Harsha  L
authors.initials: H
authors.lastname: Prasada
mesh_terms: D002648:Child; D006801:Humans; D054559:Hyperphosphatemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D010710:Phosphates / Q000097:blood; D000069603:Sevelamer / Q000627:therapeutic use*; D015275:Tumor Lysis Syndrome / Q000097:blood / Q000150:complications*; D014527:Uric Acid / Q000097:blood
chemical_list: D010710:Phosphates; D014527:Uric Acid; D000069603:Sevelamer